A Phase Ib, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of M5049 Administered Orally in SLE and CLE Participants Treated With Standard of Care
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Enpatoran (Primary)
- Indications Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Merck KGaA
- 21 Feb 2024 Status changed from active, no longer recruiting to completed.
- 06 Sep 2023 Planned End Date changed from 14 Jul 2023 to 22 Dec 2023.
- 06 Sep 2023 Planned primary completion date changed from 14 Jul 2023 to 22 Dec 2023.